| [1] |
Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS); Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology; Emergency Intervention Committee, Chinese College of Interventionalists, et al. Consensus on clinical application of hepatic venous pressure gradient in China (2018)[J]. J Clin Hepatol, 2018, 34(12): 2526-2536.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.12.008 |
| [2] |
MCDONALD SA, BARCLAY ST, HUTCHINSON SJ, et al. Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: A national database linkage study[J]. Aliment Pharmacol Ther, 2019, 50(4): 425-434. DOI: 10.1111/apt.15320 |
| [3] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portalhy pertension[J]. J Clin Hepatol, 2016, 32(2): 203-219.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2016.02.002 |
| [4] |
de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022 |
| [5] |
GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis:Risk stratification, diagnosis, and management:2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906 |
| [6] |
GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al. Beta-blockersto prevent gastroesophageal varices inpatients with cirrhosis[J]. N Engl J Med, 2005, 353(21): 2254-2261. DOI: 10.1056/NEJMoa044456 |
| [7] |
TRIPATHl D, STANLEY AJ, HAYES PC, et al. U.K.guidelines on the management of variceal haemorrhage in cirrhotic patients[J]. Gut, 2015, 64(11): 1680-1704. DOI: 10.1136/gutjnl-2015-309262 |
| [8] |
VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): A randomised, double-blind, placebo-controlled, multicentretrial[J]. Lancet, 2019, 393(10181): 1597-1608. DOI: 10.1016/S0140-6736(18)31875-0 |
| [9] |
SHARMAM, SINGHS, DESAIV, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: A systematic review and network meta-analysis[J]. Hepatology, 2019, 69(4): 1657-1675. DOI: 10.1002/hep.30220 |
| [10] |
ABRALDES JG, VILLANUEVA C, ARACIL C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival inpatientswithcirrhosis[J]. Gastroenterology, 2016, 150(5): 1160-1170. DOI: 10.1053/j.gastro.2016.01.004 |
| [11] |
GLUUD LL, KRAG A.Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J]. ochrane Database Syst Rev, 2012, (8): CD004544. DOI: 10.1021/cs300439n |
| [12] |
MISHRASR, SHARMABC, KUMARA, et al. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: A randomized controlled trial[J]. J Hepatol, 2011, 54(6): 1161-1167. DOI: 10.1016/j.jhep.2010.09.031 |
| [13] |
Cooperation Group for the Survey of Octreotide.Efficacy of octreotide in the treatment of acute variceal bleeding in cirrhotic patients: A prospective, multicentric and randomized clinical trial[J]. Chin J Dig, 2005, 25(1): 37-40.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZHHX20050100C.htm |
| [14] |
|
| [15] |
SUHOCKI PV, LUNGREN MP, KAPOOR B, et al. Transjugular intrahepatic portosystemic shunt complications: Prevention and management[J]. Semin Intervent Radiol, 2015, 32(2): 123-132. DOI: 10.1055/s-0035-1549376 |
| [16] |
SIRAMOLPIWAT S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications[J]. World J Gastroenterol, 2014, 20(45): 16996-17010. DOI: 10.3748/wjg.v20.i45.16996 |
| [17] |
SINAGRA E, PERRICONE G, D'AMICO M, et al. Systematic review with meta-analysis: The haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther, 2014, 39(6): 557-568. DOI: 10.1111/apt.12634 |
| [18] |
|
| [19] |
Chinese Society of Spleen and Portal Hypertension Surgery, Chinese Society of Surgery, Chinese Medical Association.Expert consensus on diagnosis and treatment of esophagogastric variceal bleeding in cirrhotic portal hypertension (2019 edition)[J]. Chin J Dig Surg, 2019, 18(12): 1087-1093.(in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWK201912001.htm |
| [20] |
WIEST R, KRAG A, GERBES A. Spontaneous bacterial peritonitis:Recent guidelines and beyond[J]. Gut, 2012, 61(2): 297-310. DOI: 10.1136/gutjnl-2011-300779 |
| [21] |
SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341(6): 403-409. DOI: 10.1056/NEJM199908053410603 |
| [22] |
European Association for the Study of the Liver.EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69(2): 406-460. DOI: 10.1016/j.jhep.2018.03.024 |
| [23] |
ANGELI P, GINÈS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974. DOI: 10.1016/j.jhep.2014.12.029 |
| [24] |
GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J]. Hepatology, 2010, 51(2): 576-584. DOI: 10.1002/hep.23286 |
| [25] |
SCHRIER RW, GROSS P, GHEORGHIADE M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia[J]. N Engl J Med, 2006, 355(20): 2099-2112. DOI: 10.1056/NEJMoa065181 |
| [26] |
BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J]. Liver Transpl, 2011, 17(11): 1328-1332. DOI: 10.1002/lt.22395 |
| [27] |
BOSSEN L, KRAG A, VILSTRUP H, et al. Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J]. Hepatology, 2016, 63(6): 1968-1976. DOI: 10.1002/hep.28352 |
| [28] |
European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J]. J Hepatol, 2010, 53(3): 397-417. DOI: 10.1016/j.jhep.2010.05.004 |
| [29] |
|
| [30] |
Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34(10): 2076-2089.(in Chinese) DOI: 10.3969/j.issn.1001-5256.2018.10.007 |
| [31] |
ZHU GQ, SHI KQ, HUANG S, et al. Systematic review with net-work meta-analysis:The comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy[J]. Aliment Phamacol Ther, 2015, 41(7): 624-635. DOI: 10.1111/apt.13122 |
| [32] |
QI XL.Full-course management of portal hypertension:Simplicity is the ultimate sophistication[J]. Chin J Hepatol, 2020, 28(9): 721-723.(in Chinese)
祁小龙. 门静脉高压全病程管理:至繁归于至简[J]. 中华肝脏病杂志, 2020, 28(9): 721-723.
|
DownLoad: